Precision Biosciences (DTIL) EBIAT (2018 - 2025)
Precision Biosciences (DTIL) has disclosed EBIAT for 8 consecutive years, with $19.2 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 208.47% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$46.6 million through Dec 2025, down 750.33% year-over-year, with the annual reading at -$46.6 million for FY2025, 750.33% down from the prior year.
- EBIAT for Q4 2025 was $19.2 million at Precision Biosciences, up from -$21.8 million in the prior quarter.
- The five-year high for EBIAT was $32.7 million in Q2 2024, with the low at -$31.0 million in Q2 2022.
- Average EBIAT over 5 years is -$12.1 million, with a median of -$18.2 million recorded in 2021.
- The sharpest move saw EBIAT skyrocketed 375.41% in 2024, then plummeted 339.46% in 2025.
- Over 5 years, EBIAT stood at -$22.3 million in 2021, then dropped by 27.81% to -$28.5 million in 2022, then soared by 42.82% to -$16.3 million in 2023, then decreased by 8.94% to -$17.7 million in 2024, then surged by 208.47% to $19.2 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at $19.2 million, -$21.8 million, and -$23.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.